GlassScriptPhysician profile
Tiffany M Hale
NPI 1225498819
$893.56
in general payments reported to CMS, 2019-2025
14 companies · $379 in 2025
The $379 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $186 · 2024: $329 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $893.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $137.28 | 2024-2025 | Darzalex, Tecvayli, Talvey |
| Sumitomo Pharma America, INC. | $126.94 | 2023 | Orgovyx |
| Astrazeneca Pharmaceuticals LP | $118.82 | 2024-2025 | Imfinzi, Calquence, Lynparza |
| Genentech USA, INC. | $97.30 | 2023-2025 | Polivy, Lunsumio, Tecentriq Hybreza |
| Takeda Pharmaceuticals U.S.A., INC. | $89.78 | 2024 | Fruzaqla |
| Novartis Pharmaceuticals Corporation | $86.68 | 2023-2025 | |
| Abbvie INC. | $52.22 | 2024-2025 | |
| Amgen INC. | $32.83 | 2024 | Imdelltra (Amg 757) |
| Jazz Pharmaceuticals INC. | $29.31 | 2024 | |
| Array Biopharma INC | $29.30 | 2025 | Mektovi, Xalkori, Lorbrena |
| Incyte Corporation | $24.63 | 2025 | Jakafi |
| E.R. Squibb & Sons, L.L.C. | $24.14 | 2025 | Opdivo |
| Daiichi Sankyo INC. | $23.16 | 2024 | Enhertu |
| Genmab U.S., INC. | $21.17 | 2023 | Epkinly |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Hale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.